Topics

Clinical Trials About "SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC" RSS

05:34 EST 18th February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC" on BioPortfolio

We have published hundreds of SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC news stories on BioPortfolio along with dozens of SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Clinical Trials and PubMed Articles about SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Companies in our database. You can also find out about relevant SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Drugs and Medications on this site too.

Showing "SBRT Combination With Sintilimab Treatment Advanced NSCLC" Clinical Trials 1–25 of 32,000+

Extremely Relevant

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.


Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

This is an open label, multi-center, randomized control phase II trial, to compare the efficacy and safety of sintilimab combined with anlotinib versus standard platinum-based chemotherapy as a first-line treatment in advanced NSCLC patients without driven-gene mutations.

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with concurrent stereotactic body radiation therapy (SBRT) and low dose radiotherapy (LDRT) in treating patients with stage IV non-small cell lung cancer (NSCLC). About 45 participants will be enrolled in this study. All will take part at West China Hospital, Sichuan University.


A Phase I PK Similarity Study of Sintilimab by Different Production Process in Advanced or Metastatic NSCLC Patients

this is a phase I study comparing PK similarity of sintilimab by different production process (approved versus M1b) in Chinese advanced or metastatic NSCLC patients who have failed or been intolerant to at least one prior line of standard treatment

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

This study is a single-center, randomized controlled, phase II clinical trial, aiming at giving a comparison of Sintilimab and Pembrolizumab in stage IIIB-IV NSCLC patients at first-line treatment setting.

SinTilimab After Radiation (STAR Study)

This is a single-arm phase II study, to investigator the efficacy and safety of sintilimab after radiation in advanced NSCLC, who had failed first line systemic therapy.

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

This is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received first-generation EGFR-TKIs resistance along with T790M negative.

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Recurrent Squamous NSCLC

Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC

Sintilimab and IBI305 Plus Chemotherapy (Pemetrexed ± Cisplatin) for EGFRm+ Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in Chinese non-squamous NSCLC patients with EGFRm+ after EGFR-TKI failure will be investigated in this clinical trial

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Recurrent Non-squamous NSCLC

Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Non-squamous NSCLC

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC

This is an open label, multi-center, randomized, control phase III trial, to compare the efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported care (BSC), in unresectable stage III NSCLC patients who do not experience disease progression after initial concurrent chemoradiation.

The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

Sintilimab in Combination With Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant Therapy in patients With Resectable Locally Advanced Gastric Cancer

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the treatment of stage IV NSCLC patients who failed in second-line chemotherapy.

Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

This is a single-arm, open-label and exploratory clinical study of Anlotinib Hydrochloride Capsules combined with Sintilimab injection in the treatment of advanced Hepatocellular Carcinoma (HCC). In oder to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with Sintilimab injection. Subjects with pathological confirmed Hepatocellular Carcinoma will be enrolled. 21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilim...

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label,Multi-center Study. The primary endpoint is overall survival.

A Phase Ib/II Study of Fruquintinib in Combination With Sintilimab in Patients With Advanced Solid Tumor

This study is composed of dose escalation stage and dose expansion stage. In dose escalation stage, patients with advanced solid tumor will be enrolled and administrated with Fruquintinib in combination with Sintilimab. The MTD ( maximum tolerated dose) or RP2D ( Recommended Phase 2 Dose) will be determined in this stage. In dose expansion stage, additional patients will be enrolled and be treated at RP2D to evaluate the safety, tolerability and efficacy.

FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer

Based on promising data from our laboratory demonstrating synergy between ablative local radiotherapy and FLT3 ligand immunotherapy in murine NSCLC models, investigators are performing a phase II study combining FLT3L immunotherapy and SBRT for patients with advanced NSCLC that has progressed following standard systemic therapy. All patients will receive daily subcutaneous injections of CDX-301 (75 µg/kg) for 5 days, beginning on the first day of SBRT. SBRT will be delivered t...

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer

This is a phase II study to evaluate the efficacy and safety of combination of sintilimab (PD-1 inhibitor) , apatinib and chemotherapy in unresectable advanced gastric cancer patients with oligo metastasis. This study was designed as single arm with fixed number of participants.

An Phase II Study of First-line Treatment of Advanced Colorectal Cancer With Anlotinib Plus Sintilimab

This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with R-CHOP in patients with treatment-naive EBV+ DLBCL.

Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )

Clinical studies related to immunotherapy of HNSCC have shown that PD1 monoclonal antibody has better clinical benefits than conventional chemotherapy. This phase II clinical study is a single arm, open, single-center study. The aim of this study is to observe and evaluate the efficacy and safety of Sintilimab combined with paclitaxel-albumin-binding for injection in patients with advanced recurrent and metastatic HNSCC who fail to receive first-line or more treatment. Particip...

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression. For multiple metastases in patients with advanced NSCLC, increased local treatment may benefit to prolong patient survival. This study investigated the benefits of icotinib limited systemic disease progression and continuation of Stereotactic Body Radiation Therapy,in patients with metastatic EGFR-mutant NSCLC.

Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC)

SBRT to deliver a boost dose to residual primary tumor after definitive doses of standard EBRT have been delivered concurrently with chemotherapy. Serum levels of TGF-Beta1 and correlation with SBRT toxicity.


More From BioPortfolio on "SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC"

Quick Search